Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Unknown 5Recruiting 3Completed 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Hepatocellular 19Stomach Neoplasms 12Colorectal Neoplasms 10Rectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Esophageal Squamous Cell Carcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Lung Neoplasms 3Triple Negative Breast Neoplasms 2Endometrial Neoplasms 2Turcot syndrome 1Thyroid Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Spinocerebellar Degenerations 1Sarcoma 1Salivary Gland Malignant Neoplasms 1Resectable NSCLC 1Recurrence 1Rare Tumor 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms 1NSCLC 1Microsatellite Stable Metastatic Colorectal Cancer 1Metastatic Gastroesophageal Junction Adenocarcinoma 1

Interventions

pembrolizumab 49Carboplatin 44Magnetic Resonance Spectroscopy 40Specimen Handling 39Pemetrexed 34Cisplatin 25Blood Specimen Collection 25durvalumab 17Paclitaxel 16osimertinib 15Radiotherapy 15Radiosurgery 15Bevacizumab 15Gemcitabine 14atezolizumab 13Nivolumab 13Biopsy 13Drug Therapy 12Standard of Care 10Practice Guidelines as Topic 10Immunoglobulin G 10Docetaxel 10130-nm albumin-bound paclitaxel 10X-Rays 9Taxes 9Educational Status 9Disulfides 9tislelizumab 8Etoposide 8Cetuximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Lung Neoplasms × sintilimab × Clear all
NCT03872661 2026-04-21

NIBCUN

Sun Yat-sen University

Phase 2 Recruiting
36 enrolled
Thoracic

Lung Neoplasms

NCT04973293 2024-11-19

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Ruijin Hospital

Phase NA Recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06421298 2024-05-20

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Beijing Chest Hospital, Capital Medical University

Phase 2 Recruiting
30 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡